Vaginal Estradiol vs Oral Beta-3 Agonist for Overactive Bladder Syndrome
Condition(s):Overactive Bladder SyndromeLast Updated:November 14, 2022Recruiting
Hide Studies Not Open or Pending
Condition(s):Overactive Bladder SyndromeLast Updated:November 14, 2022Recruiting
Condition(s):Overactive Bladder; PharmacokineticsLast Updated:July 2, 2013Completed
Condition(s):Urge Incontinence; Urinary Incontinence, UrgeLast Updated:April 16, 2019Completed
Condition(s):Nocturnal EnuresisLast Updated:August 3, 2023Recruiting
Condition(s):Healthy Volunteers; Pharmacokinetics of MirabegronLast Updated:July 3, 2013Completed
Condition(s):Overactive BladderLast Updated:July 2, 2013Completed
Condition(s):Type 2 DiabetesLast Updated:August 22, 2018Completed
Condition(s):Urinary Bladder Overactive; Overactive Bladder; Urinary Bladder Diseases; Urologic DiseasesLast Updated:October 22, 2018Completed
Condition(s):Ureteral Stent; Stent Related SymptomsLast Updated:November 23, 2021Unknown status
Condition(s):Overactive BladderLast Updated:December 28, 2023Completed
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.